Michael L. Goris
Academic Appointments
- Professor, Radiology - Nuclear Medicine
- Member, Cancer Center
Contact Information
-
Clinical Offices
Nuclear Medicine 300 Pasteur Dr H0250 MC 5281 Stanford, CA 94305 Tel Work (650) 725-4713 Fax (650) 498-5047Practices at Stanford Hospital and Clinics and Lucile Packard Children's Hospital
- Academic Offices
Personal Information EmailNot for medical emergencies or patient use
Professional Snapshot
Clinical Focus
- Nuclear Medicine
- Nuclear Medicine, Pediatric
- Radioimmunotherapy
- Nuclear Cardiology
Administrative Appointments
- Chairman, University panel on Radiation safety (2003 - 2010)
Professional Education
| Board Certification: | Nuclear Medicine, American Board of Nuclear Medicine (1973) |
| Residency: | Akademisch Ziekunhuis, Belgium (1969) |
| Internship: | Akademisch Ziekunhuis, Belgium (1967) |
| Medical Education: | Katholieke Universiteit Leuven, Belgium (1967) |
| Licenciaat: | KUL, Medical sciences (1978) |
Scientific Focus
Current Research Interests
Radio-immunotherapy.
Medical Imaging Processing.
Quantification for diagnosis
Clinical validations
Clinical Trials
- Assessing the suitability of an imaging probe for use in clinical cell and gene therapy trials in cancer and rheumatoid arthritis Recruiting
- Phase III CHOP + Rituximab vs CHOP + Iodine-131 Monoclonal Anti-B1 Antibody for New Dx Foll NHL Recruiting
- Study of Bexxar Combined With External Beam Radiation Therapy for Patients With Relapsed, Bulky Non-Hodgkin's Lymphoma Recruiting
- Study of Bexxar Combined with External Beam Radiation Therapy for Patients with Relapsed, Bulky Non-Hodgkin's Lymphoma Recruiting
- 90Y-IBRITUMOMAB Tiuxetan and AHCI with HD Chemotherapy and Autologous Transplantation for Relapsed or Resistant NHL No longer recruiting
Publications
- Incorporating cone-beam CT into the treatment planning for yttrium-90 radioembolization. J Vasc Interv Radiol. 2009; (5): 606-13
- Combined 18F-FDG and Fluoride Approach in PET/CT Imaging: Is There a Clinical Future? J Nucl Med. 2009
- (131)I-Tositumomab (Bexxar(R)) vs. (90)Y-Ibritumomab (Zevalin(R)) Therapy of Low-Grade Refractory/Relapsed Non-Hodgkin Lymphoma. Mol Imaging Biol. 2009
- Tumor Metabolic Phenotypes on 18F FDG PET. J Nucl Med. 2009
- Sampling density for the quantitative evaluation of air trapping. Pediatr Radiol. 2009; (3): 221-5

